Diabetic Nephropathy Clinical Trial
For diabetic patient with persisted albuminuria under the intensive control on blood pressure and blood glucose, the non-invasive method of acupressure at Sanyinjiao (SP6) is easy to use and significantly effect on albuminuria reduction in patients of diabetic nephropathy.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | December 2019 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. age between 20 and 80 years old; 2. HbA1c was lower than 9% according to the NGSP(National Glycohaemoglobin Standardisation Programme); 3. estimated glomerular filtration rate (eGFR) was more than 60 mL/min/1.73 m2. Exclusion Criteria: 1. Hyperglycemic crisis, including HHS(hyperglycemic hyperosmolar syndrome) and DKA(diabetic ketoacidosis ); 2. Persist diabetes poorly control, Hemoglobin A1c [HbA1c] >9%; 3. Endocrine disorders: such as abnormal function of thyroid, pituitary, and sex glands; 4. heart diseases:such as arrhythmia, myocardial infarction, heart failure, or installed pacemaker; 5. immune and allergic diseases: such as systemic lupus erythematosus and asthma; 6. liver or kidney dysfunction: GOT or GPT(glutamate-pyruvate transaminase ) > 80 IU/L, eGFR<60 (mL/min); 7. pregnant or lactating women; 8. less than 6months postpartum; 9. acute illness, fever, Lower urinary tract infection, NSAID(nonsteroidal antiinflammatory drug) administration; 10. physical dysfunction because of stroke. |
Country | Name | City | State |
---|---|---|---|
Taiwan | Mackay Memerial Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
Mackay Memorial Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | urinary spot albumin creatine excretion ratio (UACR) change | 8 week duratoin |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04562025 -
Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy
|
N/A | |
Not yet recruiting |
NCT03658317 -
Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy
|
N/A | |
Completed |
NCT02276196 -
Effect of LIXIsenatide on the Renal System
|
Phase 4 | |
Completed |
NCT02251067 -
Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients
|
Phase 2 | |
Completed |
NCT02829177 -
Microalbuminuria and Allopurinol in Type 1 Diabetes
|
Phase 4 | |
Completed |
NCT01440257 -
A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria
|
Phase 2 | |
Active, not recruiting |
NCT01273675 -
An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy
|
N/A | |
Terminated |
NCT01129557 -
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
|
Phase 4 | |
Completed |
NCT00317954 -
Spironolactone in Diabetic Nephropathy
|
Phase 4 | |
Active, not recruiting |
NCT02237352 -
Mechanisms of Diabetic Nephropathy in Ecuador
|
||
Not yet recruiting |
NCT05061459 -
The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy
|
||
Completed |
NCT01935167 -
To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy
|
Phase 2 | |
Recruiting |
NCT01673204 -
Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy
|
Phase 4 | |
Completed |
NCT01726816 -
Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
|
Phase 2 | |
Recruiting |
NCT01458158 -
Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease
|
N/A | |
Completed |
NCT01476501 -
Vitamin D Supplementation in Diabetic Nephropathy
|
Phase 2 | |
Completed |
NCT01447147 -
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
|
Phase 2 | |
Completed |
NCT01003236 -
Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy
|
Phase 2 | |
Completed |
NCT00535925 -
Nephropathy In Type 2 Diabetes and Cardio-renal Events
|
Phase 4 | |
Completed |
NCT00097955 -
Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria
|
Phase 2 |